Q-omics provides the consensus-scored NDP profile across patient tissues and cancer cell-line models. NDP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, NDP is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, NDP protein abundance shows 17,306 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UCEC, LUAD, and HNSC as cancer lineages where NDP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDP survival associations across molecular data types. NDP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDP RNA expression–survival associations across cancer types. High NDP expression shows unfavorable associations in STAD, ACC, ESCA and KIRP, but favorable associations in UCEC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for NDP RNA expression.
This table summarizes NDP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NDP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDP shows lower tumor expression in UCEC and PRAD and higher tumor expression in LUAD, COAD, LIHC and LUSC. The LUAD box plot shows higher NDP RNA expression in tumor versus normal tissue (log2 FC = +0.661, t-test p < 0.001).
This table shows molecular features associated with NDP in patient tissues and cancer cell lines. In patient samples, NDP shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, NDP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
